Doxorubicin liposomal (Innomedica)
多柔比星脂质体（Innomedica）
Report date: 2024/12/03 20:00:08
Base Information
Drug NameDoxorubicin liposomal (Innomedica)
Drug Alias Name
Classification
Mechanisms of Action +[4]
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInnoMedica Holding AG
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesSwiss Group for Clinical Cancer Research (SAKK)
Active IndicationsN/A
Inactive Indications